事業成果物名 |
2018年度事業成果報告書
|
||||||||
団体名 |
|||||||||
事業成果物概要 |
事業成果物：
研究成果は、国内外の学会等に報告し、あるいは原著論文として論文発表を行った。学会発表等は省略し、英文原著論文のみを記載する。 研究１ がん幹細胞の特性の解析と阻害剤の開発 1. Suenaga M, Wakatsuki T, Mashima T, Ogura M, Ichimura T, Shinozaki E, Nakayama I, Osumi H, Ota Y, Takahari D, Chin K, Seimiya H, Yamaguchi K. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Invest New Drugs, In press, 2019. 2. Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, Watanabe H, Honma T, Umehara T, Shirouzu M, Okue M, Kano Y, Watanabe T, Kitamura K, Shitara E, Muramatsu Y, Yoshida H, Mizutani A, Seimiya H, Yoshida M, Koyama H. Discovery of novel Spiroindoline derivatives as selective tankyrase inhibitors. J Med Chem, In press, 2019. 3. Okamoto K, Seimiya H. Revisiting Telomere Shortening in Cancer. Cells, 8: E107, 2019. 4. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz H-J. Gene polymorphisms in the CCL5/CCR5 pathway as genetic biomarker for outcome and hand-foot skin reaction in metastatic colorectal cancer patients treated with regorafenib. Clin Colorectal Cancer, 17: e395-e414, 2018. 5. Fujiwara C, Muramatsu Y, Nishii M, Tokunaka K, Tahara H, Ueno M, Yamori T, Sugimoto Y, Seimiya H. Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Sci Rep, 8: 14827, 2018. 6. Mizutani A, Yashiroda Y, Muramatsu Y, Yoshida H, Chikada T, Tsumura T, Okue M, Shirai F, Fukami T, Yoshida M, Seimiya H. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Sci, 109: 4003-4014, 2018. 研究２ がんにおける薬剤耐性、環境応答異常の分子機構と「がん幹細胞」 1. Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med, In press, 2019. 2. Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine, 41: 105-119, 2019. 3. Sakamoto K, Katayama R, Asaka R, Sakata S, Baba S, Nakasone H, Koike S, Tsuyama N, Dobashi A, Sasaki M, Ichinohasama R, Takakuwa E, Yamazaki R, Takizawa J, Maeda T, Narita M, Izutsu K, Kanda Y, Ohshima K, Takeuchi K. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia, 32: 2590-2603, 2018. 4. Gong B, Oh-Hara T, Fujita N, Katayama R. 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer. Biochem Biophys Res Commun, 501: 527-533, 2018. 5. Uchibori K, Inase N, Nishio M, Fujita N, Katayama R. Identification of mutation accumulation as resistance mechanism emerging in first-line Osimertinib treatment. J Thorac Oncol, 13: 915-925, 2018. 6. Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer. Lung Cancer, 117: 16, 2018. 研究３ がん転移の分子機構と「がん幹細胞」の役割、その阻害剤開発 1. Ukaji T, Takemoto A, Katayama R, Takeuchi K, Fujita N. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget, 9: 33322-33336, 2018. 2. Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach E, Sheehan S, Takemoto A, Chang YW, Yoneda K, Asai J, Jensen L, Chalise L, Natsume A, Goldberg G. Podoplanin – an emerging cancer biomarker and therapeutic target. Cancer Sci, 109: 1292-1299, 2018. 研究４ 細胞パネルスクリーニングによる抗がん剤の開発研究と支援 1. Kodaka A, Hayakawa Y, AlSayegh RJ, Yasuhara T, Tomoda H, Oku T, Dan S, Tsuiji M, Tsuji T. Stereoisomer specific induction of G2/M phase arrest and apoptosis by 9-(E, Z)-hydroxyoctadecadienoic acid in mouse lymphoma cells. Biol Pharm Bull, In press, 2019. 2. Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y, Okuyama H, Okami J, Imamura F, Ohue M, Kato K, Nomura T, Kohara A, Mori S, Dan S, Inoue M. High-throughput screening in colorectal cancer tissue-originated spheroids. Cancer Sci, 110: 345-355, 2019. 3. Hayakawa K, Hanaki Y, Tokuda H, Yanagita R, Nagahara Y, Okamura M, Dan S, Irie K. Synthesis and Biological Activities of Acetal Analogs at Position 3 of 10-Methyl-Aplog-1, A Potential Anti-Cancer Lead Derived from Debromoaplysiatoxin. Heterocycles, 97: 478-492, 2018. 4. Namatame N, Tamaki N, Yoshizawa Y, Okamura M, Nishimura Y, Yamazaki K, Tanaka M, Nakamura T, Semba K, Yamori T, Yaguchi SI, Dan S. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines. Oncotarget, 9: 35141-35161, 2018. 5. Ohashi Y, Okamura M, Katayama R, Fang S, Tsutsui S, Akatsuka A, Shan M, Choi HW, Fujita N, Yoshimatsu K, Shiina I, Yamori T, Dan S. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget, 9: 1641-1655, 2018. 6. Kitamura K, Itoh H, Sakurai K, Dan S, Inoue M. Target Identification of Yaku'amide B and Its Two Distinct Activities against Mitochondrial FoF1-ATP Synthase. J Am Chem Soc, 140: 12189-12199, 2018. |
||||||||
助成機関 |
|||||||||
事業成果物種類 |
論文
|
||||||||
事業成果物 |
|
